Back grey_arrow_rt.gif
 
Latest articles on Hepatitis B.
 
null.gif
 
 
  1. EASL: An open-label, comparative, multicentre study of peginterferon alfa-2a (40KD) plus ribavirin in the treatment of patients chronically infected with HCV/HBV or HCV alone - (05/15/08)
     
  2. EASL: On-treatment HBsAg decline in HBeAg-negative patients as a predictor of response to peginterferon alfa-2a (40KD) therapy 3 years off-treatment: potential for response-guided therapy - (05/15/08)
     
  3. EASL: HBV DNA suppression induced by peginterferon alfa-2a (40KD) but not by lamivudine results in HBsAg clearance and seroconversion at 3 years off-treatment - (05/15/08)
     
  4. EASL: Efficacy and safety of peginterferon alfa-2a (40KD) in Chinese patients with HBeAg-positive chronic hepatitis B - (05/15/08)
     
  5. EASL: Virological and biochemical response in patients with HBeAg-negative chronic hepatitis B treated with PEGASYS with or without lamivudine: results of 4-year follow-up: 11% HBsAg Clearance - (05/02/08)
     
  6. EASL: Entecavir (ETV) Results in Higher HBV DNA Reduction versus Adefovir (ADV) in Antiviral-naive HBeAg(+) Adults with High HBV DNA: Week 96 Results (E.A.R.L.Y. Study) - (05/01/08)
     
  7. EASL: Important Progress Toward Control of Hepatitis B and C - (05/01/08)
     
  8. EASL: Increasing HBV Viral Load Increases Risk for Liver Cancer--Serial Monitoring of Viral load and Serum Alanine Aminotransferase (ALT) Level and the Risk of Hepatocellular Carcinoma: R.E.V.E.A.L- HBV Study Update - (04/30/08)
     
  9. EASL: Three Years of Continuous Treatment with Entecavir Results in High Proportions of Chinese Nucleoside-Naive Patients with Undetectable HBV DNA: Results from Studies ETV-023 and -050 - (04/30/08)
     
  10. EASL: Three Years of Continuous Treatment in Chinese Patients who had Previously Failed Lamivudine: Results from Studies ETV-056 and ETV-050 - (04/30/08)
     
  11. EASL: Long Term (3 Years) Efficacy, Safety and Resistance Analyses of Entecavir (ETV) Treatment in Japanese Nucleoside-naive Patients with Chronic Hepatitis B (CHB) - (04/30/08)
     
  12. EASL: Increasing Serial HBV Viral Load & ALT Predicts HCC - (04/29/08)
     
  13. EASL: BARACLUDE (ENTECAVIR) TREATMENT RESULTED IN GREATER VIRAL LOAD SUPPRESSION COMPARED TO ADEFOVIR AT 96 WEEKS IN ANTIVIRAL-NAIVE ADULT CHRONIC HEPATITIS B E-ANTIGEN POSITIVE PATIENTS - (04/29/08) BMS press release
     
  14. EASL: Hepatitis B an issue 'too hot to handle' in Australia - (04/29/08)
     
  15. EASL: A MULTICENTER ANALYSIS OF ANTIVIRAL RESPONSE AFTER ONE YEAR OF TENOFOVIR MONO-THERAPY IN HBV MONO-INFECTED PATIENTS WITH PRIOR NUCLEOS(T)IDE ANALOGUE EXPERIENCE - (04/29/08)
     
  16. EASL: The Antiviral Response To Tenofovir Disoproxil Fumarate (TDF) is Comparable in Lamivudine (LAM)-NaIve and LAM-Experienced Subjects Treated for Chronic Hepatitis B (CHB) - (04/29/08)
     
  17. EASL: Tenofovir Disoproxil Fumarate (TDF) is Highly Active for Treatment of Chronic Hepatitis B (CHB) in Patients With Cirrhosis - (04/29/08)
     
  18. EASL: Tenofovir Disoproxil Fumarate (TDF) for the Treatment of HBeAg-Negative Chronic Hepatitis B: Week 72 TDF Data and Week 24 Adefovir Dipivoxil Switch Data (Study 102) - (04/29/08)
     
  19. EASL: Tenofovir Disoproxil Fumarate (TDF) for the Treatment of HBeAg-Positive Chronic Hepatitis B: Week 72 TDF Data and Week 24 Adefovir Dipivoxil Switch Data (Study 103) - (04/29/08)
     
  20. EASL: Tenofovir Disoproxil Fumarate (TDF) Versus Emtricitabine Plus TDF for Treatment of Chronic Hepatitis B (CHB) in Subjects with Persistent Viral Replication Receiving Adefovir Dipivoxil (ADV) - (04/29/08)
     
  21. EASL: Liver Disease Progression in Chronic Hepatitis B Infected Persons With Persistently Normal Serum Alanine Aminotransferase Level: Update From the R.E.V.E.A.L.-HBV Study - (04/29/08)
     
  22. EASL: Tenofovir Disoproxil Fumarate (TDF) Versus Emtricitabine Plus TDF for Treatment of Chronic Hepatitis B (CHB) in Subjects with Persistent Viral Replication Receiving Adefovir Dipivoxil (ADV) - (04/29/08)
     
  23. EASL: European Commission Approves Viread(R) for Chronic Hepatitis B - (04/25/08)
     
  24. EASL: GILEAD ANNOUNCES 72-WEEK DATA FROM TWO PIVOTAL PHASE III STUDIES EVALUATING VIREAD (tenofovir) FOR THE TREATMENT OF CHRONIC HEPATITIS B - (04/24/08)
     
  25. Chronic Hepatitis B: Preventing, Detecting, and Managing Viral Resistance - (04/21/08)
     
  26. Entecavir Therapy Induces de Novo HIV Reverse-Transcriptase M184V Mutation in an Antiretroviral Therapy-Naive Patient BRIEF REPORT - (04/04/08)
     
  27. APASL: Entecavir at Five Years Shows Long Long-Term Maintenance of High Genetic Barrier to Hepatitis B Virus Resistance - (03/25/08)
     
  28. APASL: BARACLUDE (ENTECAVIR) DATA CONTINUE TO DEMONSTRATE LOW INCIDENCE OF RESISTANCE THROUGH FIVE YEARS OF TREATMENT IN NUCLEOSIDE-NAIVE CHRONIC HEPATITIS B PATIENTS (BMS press announcement) - (03/25/08)
     
  29. APASL: Efficacy and Safety of 3 Years Treatment with Entecavir (ETV) in Japanese Nucleoside-Naive Patients with Chronic Hepatitis B (CHB) - (03/25/08)
     
  30. APASL: Three Years of Continuous Treatment in Chinese Patients who had Previously Failed Lamivudine: Results from Studies ETV-056 and ETV-050 - (03/25/08)
     
  31. EUROPEAN CHMP ISSUES POSITIVE OPINION FOR VIREAD (tenofovir) FOR THE TREATMENT OF CHRONIC HEPATITIS B - (03/20/08)
     
  32. HIV and hepatitis B co-infection in Africa Reflection and Reaction - (03/20/08)
     
  33. Clinical implications of HIV and hepatitis B co-infection in Asia and Africa Review - (03/20/08)
     
  34. CROI: Immunopathogenesis of Hepatic Flares after Initiation of ART in HIV/HBV-co-infected Individuals - (03/19/08)
     
  35. Occult hepatitis B virus in liver tissue of individuals without hepatic disease - (03/14/08)
     
  36. Combination therapy for chronic hepatitis B: Ready for prime time? Editorial - Written by Ira M. Jacobson - (03/10/08)
     
  37. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations - (03/05/08)
     
  38. Potency of tenofovir in chronic hepatitis B: Mono or combination therapy? Editorial - (03/05/08)
     
  39. Goal of HBV Therapy - Prevent Resistance - (01/07/08)
     
  40. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART - (12/12/07)
     
  41. Thousands of Canadians may be denied access to effective new hepatitis B treatment: Drug review committee recommends against full reimbursement of Baraclude (TM) (entecavir) - (12/05/07)
     
  42. Hepatitis B Clinical Research Network Starts - (12/04/07)
     
  43. The clinical significance of persistently normal ALT in chronic hepatitis B infection - (12/04/07)
     
  44. Frequent Occurrence of Chronic Hepatitis B Virus Infection among West African HIV Type-1-Infected Children - (01/03/08)
     
  45. Hepatitis B Virus and HIV Coinfection in Low-Income Countries: Unmet Needs EDITORIAL COMMENTARY - (01/03/08)
     
  46. Tenofovir-Based Rescue Therapy for Advanced Liver Disease in 6 Patients Coinfected with HIV and Hepatitis B Virus and Receiving Lamivudine BRIEF REPORT - (01/03/08)
     
  47. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART - (12/12/07)
     
  48. Thousands of Canadians may be denied access to effective new hepatitis B treatment: Drug review committee recommends against full reimbursement of Baraclude(TM) (entecavir) - (12/05/07)
     
  49. Hepatitis B Clinical Research Network Starts - (12/04/07)
     
  50. The clinical significance of persistently normal ALT in chronic hepatitis B infection - (12/04/07)
     
  51. New wave of immigration blamed for doubling of hepatitis B cases in UK - (11/28/07)
     
  52. Most UK citizens susceptible to hep B infection - (11/28/07)
     
  53. Impact of chronic hepatitis C and/or D on liver fibrosis severity in patients co-infected with HIV and hepatitis B virus - (11/27/07)
     
  54. AASLD: Decline in the Need for Liver Transplantation for Endstage Liver Disease Secondary to Hepatitis B in the US - (11/26/07)
     
  55. Entecavir Therapy for up to 96 Weeks in Patients With HBeAg-Positive Chronic Hepatitis B - (11/19/07)
     
  56. Low Resistance to Adefovir Combined With Lamivudine: A 3-Year Study of 145 Lamivudine-Resistant Hepatitis B Patients - (11/19/07)
     
  57. Hepatitis B: Explosion of New Knowledge; Comments by E Keefe - (11/19/07)
     
  58. AASLD: Reduction in serum HBsAg level in patients with chronic hepatitis B infected with genotype D induced by (pegylated) interferon alfa-2a alone or in combination with nucleos(t)ide analogs: a long-term single centre cohort study - (11/16/07)
     
  59. AASLD: Long-term follow-up of HBsAg clearance in patients with HBeAg-negative CHB treated with peginterferon alfa-2a (PEGASYS): increase in HBsAg clearance rate from 3% 6 months post-treatment to 8% after 3 years - (11/16/07)
     
  60. AASLD: An Open Label, Comparative, Multicenter Study Of Peginterferon Alfa-2a Plus Ribavirin In The Treatment Of Patients With Chronic Hepatitis C/Hepatitis B Dual Infection Versus Those With Chronic Hepatitis C Mono-infection - (11/16/07)
     
  61. AASLD: Real-Time PCR Quantification of Total Intracellular HBV DNA and cccDNA in HBsAg-Positive Patients with and without HDV co-Infection and in Patients with Occult HBV Infection - (11/16/07)
     
  62. AASLD: First Multicenter Evaluation of the Efficacy of Tenofovir in Nucleo(t)ide Analog Experienced Patients with HBV Monoinfection - (11/14/07)
     
  63. AASLD: Efficacy of Tenofovir DF for the Treatment of Adefovir Resistance - (11/14/07)
     
  64. AASLD: Fatty Liver Associated with Metabolics in HBV+ - (11/14/07)
     
  65. AASLD: Large Scale Longitudinal Study of Chronic Hepatitis B Patients with Hepatitis B Surface Antigen Seroclearance - (11/7/07)
     
  66. AASLD: A Randomized, Double-Blind, Comparison of Tenofovir DF (TDF) versus Adefovir Dipivoxil (ADV) for the Treatment of HBeAg Positive Chronic Hepatitis B (CHB): Study GS-US-174-0103 - (11/7/07)
     
  67. AASLD: A Randomized, Double-Blind, Comparison of Tenofovir DF (TDF) versus Adefovir Dipivoxil (ADV) for the Treatment of HBeAg-Negative Chronic Hepatitis B (CHB): Study GS-US-174-0102 - (11/7/07)
     
  68. AASLD: HBV Viral Load Less Than 10,000 copies/mL Is Associated with Significant Risk of Hepatocellular Carcinoma in Chronic Hepatitis B (CHB) Patients: An Update from the R.E.V.E.A.L.-HBV Study - (11/7/07)
     
  69. AASLD: Impact of chronically elevated HBV DNA viral load on risk of HCC occurrence: An update from The R.E.V.E.A.L.-HBV Study - (11/7/07)
     
  70. AASLD: Changes in Serum HBV DNA Level Using a Trajectory Model to Predict the Risk of HCC in Chronic Hepatitis B Patients: The R.E.V.E.A.L.-HBV Study - (11/7/07)
     
  71. AASLD: Gilead's Tenofovir beats Hepsera in second big HBV trial - (11/7/07)
     
  72. AASLD: Four-Year Entecavir Treatment in Nucleoside-Naive, HBeAg(+) Patients: Results from Studies ETV-022 and -901 - (11/5/07)
     
  73. AASLD: Long-Term Follow-Up of Entecavir Treated Protocol-Defined 'Non-Responders' in Rollover Study ETV-901 - (11/5/07)
     
  74. Why we should routinely screen Asian American adults for hepatitis B: A cross-sectional study of Asians in California - (10/17/07)
     
  75. GILEAD SUBMITS MARKETING APPLICATIONS IN THE UNITED STATES AND EUROPEAN UNION FOR VIREAD (TENOFOVIR DISOPROXIL FUMARATE) FOR THE TREATMENT OF CHRONIC HEPATITIS B - (10/12/07)
     
  76. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV - (10/02/07)
     
  77. Report of an International Workshop: Roadmap for Management of Patients Receiving Oral Therapy for Chronic Hepatitis B - (08/20/07)
     
  78. Prevalence and Long-Term Effects of Occult Hepatitis B Virus Infection in HIV-Infected Women - (08/17/07)
     
  79. Novartis/Idenix Launch Free Telbivudine HBV Drug Program for HBV Therapy - (08/14/07)
     
  80. Screening for and Treating Hepatitis B Virus in Patients with HIV Infection EDITORIAL - (08/10/07)
     
  81. Impact of HAART) on the Natural History of Hepatitis B Virus (HBV) and HIV Coinfection: Relationship between Prolonged Efficacy of HAART and HBV Surface and Early Antigen Seroconversion - (08/10/07)
     
  82. Hepatitis B Virus and HIV Coinfection: Results of a Survey on Treatment Practices and Recommendations for Therapy - (08/10/07)
     
  83. Incidence (3 times higher) of non-Hodgkin's lymphoma among individuals with chronic hepatitis B virus infection - (07/16/07)
     
  84. Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis - (07/16/07)
     
  85. The HBV Asian Epidemic You Don't Know About - (07/06/07)
     
  86. Incidence of non-Hodgkin's lymphoma among individuals with chronic hepatitis B virus infection - (07/05/07)
     
  87. The Natural History and Treatment of Chronic Hepatitis B: A Critical Evaluation of Standard Treatment Criteria and End Points (HBV-DNA, ALT) - (07/03/07)
     
  88. SECOND PHASE III STUDY EVALUATING GILEAD'S VIREAD (Tenofovir) FOR THE TREATMENT OF CHRONIC HEPATITIS B VIRUS MEETS PRIMARY ENDPOINT - (06/27/07)
     
  89. Phase III Study Evaluating Gilead's Viread(R) for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint - (06/07/07)
     
  90. DDW: Patient survey, Many hepatitis B patients stop taking meds - (05/31/07)
     
  91. Predicting response to peginterferon a-2a (Pegasys), lamivudine and the two combined for HBeAg-negative chronic hepatitis B; genotype may predict response to combination therapy - (05/25/07)
     
  92. DDW: A Randomized Trial of Telbivudine vs Adefovir for HBeAg-Positive Chronic Hepatitis B: Efficacy Through Week 76, Predictors of Response and Effects of Switching to Telbivudine - (05/25/07)
     
  93. DDW: A Phase III Comparative Trial of Telbivudine vs Lamivudine in Chinese Patients With Chronic Hepatitis B: Two-Year Results - (05/25/07)
     
  94. DDW: Causes of Death Associated With Hepatitis B or Hepatitis C Virus Infections in a Long-Term Population-Based Cohort Study - (05/24/07)
     
  95. DDW: Salvage Therapy With Adefovir for Virologic Breakthrough in Telbivudine-Treated Patients From the GLOBE Study - (05/23/07)
     
  96. DDW: Presence of Biopsy-Proven Histologic Damage (Necroinflammation and Fibrosis) is Common Even When ALT is Less Than 2 x ULN in Patients with Chronic Hepatitis B (CHB) in Entecavir Studies ETV-022 (HBeAg+) and ETV-027 (HBeAg-) - (05/23/07)
     
  97. DDW: Genotypic Analysis of Patients with Evaluable HBV DNA After 1 Year of Telbivudine Therapy in the GLOBE Registration Trial - (05/23/07)
     
  98. DDW: Resistance Determination in Patients Experiencing Virologic Breakthrough Following Telbivudine or Lamivudine Therapy in the International GLOBE Trial - (05/23/07)
     
  99. DDW: BARACLUDE (ENTECAVIR) TREATMENT DEMONSTRATED GREATER VIRAL LOAD REDUCTION COMPARED TO ADEFOVIR AT 48 WEEKS IN STUDY OF ANTIVIRAL-NAIVE CHRONIC HEPATITIS B E-ANTIGEN POSITIVE PATIENTS - (05/23/07)
     
  100. DDW: Telbivudine GLOBE Trial at Year Two: Efficacy, Safety, and Predictors of Outcome in Patients with Chronic Hepatitis B - (05/21/07)
     
  101. DDW: HBV DNA & Genotype Predict HCC - (05/21/07)
     
  102. DDW: HBV DNA & ALT Predict HCC in HBV+ - (05/21/07)
     
  103. HBV Exposure May Increase HCC Risk Among HCV+ with Cirrhosis, Japan study reports - (05/04/07)
     
  104. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B - (05/04/07)
     
  105. Novartis gets European OK for hepatitis B drug Sebivo (telbivudine) - (05/01/07)
     
  106. EASL: An open label, comparative, multi-center study of peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin in the treatment of patients with chronic hepatitis C/hepatitis B dual infection versus with mono-infected chronic hepatitis C: An interim report - (04/25/07)
     
  107. EASL: EFFECTS OF INSULIN SENSITIZING AGENTS IN NONALCOHOLIC FATTY LIVER DISEASE, METABOLICS: metformin, rosiglitazone, metformin+rosiglitazone - (04/23/07)
     
  108. EASL: 76 Week Follow-up of HBeAg-Positive Chronic Hepatitis B Patients Treated with Telbivudine, Adefovir or Switched from Adefovir to Telbivudine - (04/23/07)
     
  109. EASL: HBV rtI233V Polymerase Variant Remains Sensitive to Adefovir - (04/23/07)
     
  110. EASL: Pegasys Superior to Lamivudine Over 3 Years in HBV DNA Decline, ALT Normalization & HBsAg Loss (8% vs 0) & Seroconversion (4% vs 0) - (04/23/07)
     
  111. EASL: Peginterferon a-2a Plus adefovir vs Peginterferon a-2a for 48 Weeks in HBeAg-Negative Chronic Hepatitis B: Preliminary 24-Week Results of the PEG FOR B Randomized Multicenter Trial - (04/23/07)
     
  112. EASL: Efficacy of Entecavir and Lamivudine in Chronic Hepatitis B Patients with Advanced Liver Fibrosis/Cirrhosis - (04/19/07)
     
  113. EASL: Presence of Biopsy-Proven Histologic Damage (Necroinflammation and Fibrosis) is Common even when ALT is less than 2 X ULN in Patients with Chronic Hepatitis B - (04/19/07)
     
  114. EASL: Entecavir (ETV) Results in Higher HBV-DNA Reduction vs Adefovir (ADV) in Chronically Infected HBeAg(+) Antiviral-Naive Adults: 48-Wk Results (E.A.R.L.Y. Study) - (04/17/07)
     
  115. EASL: Four Year Assessment Of Entecavir Resistance In Nucleoside Naive and Lamivudine Refractory Patients - (04/17/07)
     
  116. EASL: Four-Year Data Demonstrate Continued Low Incidence of BARACLUDE (entecavir) Resistance in Nucleoside-naive Chronic Hepatitis B Patients (press release from BMS) - (04/17/07)
     
  117. EASL: BARACLUDE (entecavir) Therapy Resulted in Undetectable Levels of Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment (press release from BMS) - (04/17/07)
     
  118. EASL: ETV Re-treatment of Nucleoside-Naive HBeAg(-) Patients with Recurrent Viremia - (04/17/07)
     
  119. China Approves Schering-Plough's Pegintron for Hepatitis B - (04/05/07)
     
  120. Viral Hepatitis (HCV, HBV) in HIV Infection REVIEW by Margaret Koziel, Marion Peters - (04/05/07)
     
  121. CROI: Hepatitis B Virus (HBV) Dynamics in HIV-HBV Co-infected Patients: Significant Difference in the Viral Activity of Adefovir (ADV) or Tenofovir (TDF) (03/09/07)
     
  122. SEBIVO(R) (telbivudine) Recommended for Approval in European Union as a new Treatment for Patients with Chronic Hepatitis B - (02/27/07)
     
  123. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B - (02/12/07)
     
  124. Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years - (01/30/06)
     
  125. New and Emerging Treatment of Chronic Hepatitis B - (01/30/06)
     
  126. Hepatitis B Virus Treatment in HIV-infected Patients - (01/30/06)
     
  127. Effect of Lowering HBV DNA Levels by Initial Antiviral Therapy Before Adding Immunomodulator Peginterferon on Treatment of Chronic Hepatitis B - (12/17/06)
     
  128. Combination Therapy for Chronic Hepatitis B: Simultaneous or Sequential? EDITORIAL - (12/17/06)
     
  129. Idenix announces telbivudine for chronic hepatitis B patients approved in Switzerland - (12/07/06)
     
  130. A novel hepatitis B virus mutation with resistance to adefovir but not to tenofovir in an HIV-hepatitis B virus-co-infected patient - (12/07/06)
     
  131. Hepatitis B virus resistance to entecavir in nucleoside naive patients: Does it exist Editorial - (12/07/06)
     
  132. Entecavir resistance is rare in nucleoside naive patients with hepatitis B - (12/07/06)
     
  133. AASLD: No Novel Adefovir Mutations - (11/08/06)
     
  134. AASLD: Pegasys/RBV Prophylaxisly Administered After Liver Transplant - (11/08/06)
     
  135. AASLD: RBV Exposure During weeks 1-12 of Treatment Improves SVR Rate in Canadian Pegasys EAP - (11/08/06)
     
  136. AASLD: Pegasys + Adefovir Reduces HBsAg in HDV-Coinfected - (11/07/06)
     
  137. AASLD: Pegasys+Lamivudine for HBeAg-negative, 2 Year Follow-up - (11/07/06)
     
  138. AASLD: Anti-HBV Activity of In Vitro Combinations of Tenofovir with Nucleoside Analogs - (11/06/06)
     
  139. AASLD: In Vitro Susceptibility of HBV Polymerase Encoding Mutations Acquired During Adefovir Dipivoxil Therapy to Other Anti-HBV Agents - (11/06/06)
     
  140. AASLD: Entecavir Resistance 3-Year Update at AASLD - (11/02/06)
     
  141. AASLD: Entecavir 3-Year Resistance Update - (11/02/06)
     
  142. AASLD: Entecavir 3-Year Efficacy/Safety Update in HBeAg+ Naives - (11/02/06)
     
  143. AASLD: Entecavir 3-Year Update on Efficacy & Safety - (11/02/06)
     
  144. AASLD: Two-Year Results from the GLOBE Trial in Patients with Hepatitis B: Greater Clinical and Antiviral Efficacy for Telbivudine (LdT) vs Lamivudine - (11/01/06)
     
  145. ICAAC: Can Razor Blades Transmit Hepatitis B? - (10/02/06)
     
  146. World Hepatitis Awareness Day October 1, 2006 - (10/02/06)
     
  147. BMS Announces Baraclude (entecavir) Now Available In The UK For Treatment Of Chronic Hepatitis B - (09/21/06)
     
  148. Novartis wins first major nod for hep B drug - (09/21/06)
     
  149. Antiretroviral Therapy for Hepatitis B Virus-HIV-Coinfected Patients: Promises and Pitfalls - (09/18/06)
     
  150. Hepatitis C virus eradication followed by HBeAg to anti-HBe seroconversion after pegylated interferon-α2b plus ribavirin treatment in a patient with hepatitis B and C coinfection - (09/15/06)
     
  151. Treatment Alternatives for Hepatitis B Cirrhosis: A Cost-Effectiveness Analysis - (09/11/06)
     
  152. Liver transplants can be successful in HIV patients with hepatitis B - (09/07/06)
     
  153. Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: Relation to treatment response - (09/05/06)
     
  154. Past HBV Viral Load as Predictor of Mortality and Morbidity from HCC and Chronic Liver Disease in a Prospective Study - (08/01/06)
     
  155. Tenofovir disoproxil fumarate: Role in hepatitis B treatment - (08/01/06)
     
  156. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy - (08/01/06)
     
  157. Tenofovir disoproxil fumarate: Role in hepatitis B treatment - (08/01/06)
     
  158. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy - (08/01/06)
     
  159. Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B - (07/30/06)
     
  160. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: An Update - (07/27/06)
     
  161. FDA committee favors Nabi hepatitis B drug for Post-Transplant - (07/14/06)
     
  162. Hepatitis B Vaccination Coverage Among Adults --- United States, 2004 - (07/07/06)
     
  163. European Commission Grants Approval for BARACLUDE(R) (entecavir) for Treatment of Chronic Hepatitis B - (06/29/06)
     
  164. DDW: Safety and Efficacy of Adefovir Dipivoxil in Patients with Lamivudine-Resistant Chronic HBV Undergoing Liver Transplantation - (05/26/06)
     
  165. DDW: A COMPARATIVE TRIAL OF TELBIVUDINE AND ADEFOVIR DIPIVOXIL FOR TREATMENT OF HBeAg-POSITIVE, COMPENSATED CHRONIC HEPATITIS B: 24 WEEK RESULTS - (05/26/06)
     
  166. DDW: Predictive Factors for Exacerbation of Hepatitis B After Discontinuation of Oral Therapy in HBeAg-Negative Patients - (05/26/06)
     
  167. DDW: Entecavir 96 Weeks in Lamivudine-Refractory HBeAg(+): efficacy, safety, resistance - (05/26/06)
     
  168. 15% HBV Prevalence in NYC Among Asians - (05/16/06)
     
  169. EASL: HBV Resistance Determination From the Telbivudine GLOBE Registration Trial - (05/16/06)
     
  170. EASL: Pharmacokinetics and Pharmacodynamics of Pradefovir Mesylate, a Liver-Targeting Pro-Drug of PMEA, in HBV Patients - (05/16/06)
     
  171. EASL: Clevudine 48 Weeks - (05/16/06)
     
  172. EASL: Safety, Tolerability and Antiviral Activity of Pradefovir Mesylate in Patients with Chronic Hepatitis B Virus Infection: 48-Week Analysis of a Phase 2 Study - (05/16/06)
     
  173. EASL: Telbivudine, New HBV Drug: Early Viral Response Predicts Outcomes - (05/10/06)
     
  174. EASL: A Randomized Trial of Telbivudine (LdT) vs. Adefovir for HBeAg-Positive Chronic Hepatitis B: Results of the Primary Week 24 Analysis - (05/10/06)
     
  175. EASL: Association Between HBeAg Seroconversion and Sustained HBV DNA Suppression in Patients Treated with Peginterferon Alfa-2a (40 KD) (Pegasys) for HBeAg-positive Chronic Hepatitis B - (05/08/06)
     
  176. EASL: Durability of HBeAg Seroconversion Following Adefovir Dipivoxil Treatment for Chronic Hepatitis B - (05/08/06)
     
  177. Association Between HBeAg Seroconversion and Sustained HBV DNA Suppression in Patients Treated with Peginterferon Alfa-2a (40 KD) (Pegasys) for HBeAg-positive Chronic Hepatitis B - (05/05/06)
     
  178. EASL: Combination HBV Therapy (lamivudine+adefovir) Prevented HBV-DNA Viral Rebound and Adefovir Resistance Compared to Adefovir Monotherapy in Cirrhotics - (05/04/06)
     
  179. EASL: Entecavir Improved Fibrosis in Advanced Liver Disease More Than Lamivudine in 3 Pivotol Studies After 48 Weeks Therapy - (05/04/06)
     
  180. EASL: Entecavir vs Lamivudine in 515 Treatment-Naives: safety & efficacy - (05/04/06)
     
  181. Outcome of patients with hepatitis B virus and HIV referred for liver transplantation - (05/03/06)
     
  182. HBV/HIV Coinfection: Timing in Treatment & Referral for Transplantation and Suppression HBV Replication Are Crucial - (05/03/06)
     
  183. EASL: Adefovir 5 years Viral & Resistance Outcomes in HBeAg-negatives - (05/03/06)
     
  184. EASL: High Barrier To Resistance Results In No Emergence Of Entecavir Resistance In Nucleoside Naive Subjects During The First Two Years Of Therapy - (05/02/06)
     
  185. EASL: Entecavir 96 weeks in HBeAg(-), study ETV-027 - (04/19/06)
     
  186. Entecavir (ETV) vs. Adefovir (ADV): HBV DNA Reduction In Chronically Infected HBeAg(+) Nucleoside-Naive Adults In A 12-Week Viral Kinetics Study - (04/07/06)
     
  187. Lamivudine monotherapy in HBeAg-negative chronic hepatitis B: prediction of response-breakthrough and long-term clinical outcome - (04/05/06)
     
  188. Idenix Files in china for Telbivudine Approval, new HBV Drug - (04/05/06)
     
  189. Idenix Announces 13 Abstracts on Hepatitis B and C Accepted for the 2006 Annual Meeting of the European Association for the Study of the Liver (EASL) - (04/05/06)
     
  190. 48 weeks pegylated interferon alpha-2a is superior to 24 weeks of pegylated interferon alpha-2b in achieving hepatitis B e antigen seroconversion in chronic hepatitis B infection - (04/05/06)
     
  191. Role of Hepatitis B Viral Load and Basal Core Promoter Mutation in Hepatocellular Carcinoma in Hepatitis B Carriers - (04/05/06)
     
  192. Novartis files telbivudine in China for Hep B - (03/29/06)
     
  193. Personal view: the management of chronic hepatitis B infection - (03/21/06)
     
  194. HBV Drug Pradefovir Phase 2 48 Week Study Results - (03/15/06)
     
  195. Management of Recurrent Viral Hepatitis B and C After Liver Transplantation - (03/15/06)
     
  196. HBV DNA Early Response Predicts IFN Nonresponse - (03/15/06)
     
  197. Entecavir, Hepatitis B Drug Phase III Study Results in HBsAg - (03/09/06)
     
  198. Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B - (03/09/06)
     
  199. Hepatitis Delta Virus Levels May Predict Disease Severity in HBV - (03/09/06)
     
  200. CROI: Tenofovir + Lamivudine (3TC) for HBV/HIV Coinfection (03/07/06)
     
  201. Tenofovir in HBV/HIV Coinfection, added to Lamivudine - (03/03/06)
     
  202. Combination therapy for chronic hepatitis B: A one-two knockout punch, or a swing and a miss? - (03/03/06)
     
  203. CROI: Hepatitis D Virus Can Worsen the Outcome of HBV-HIV Coinfected Patients (02/23/06)
     
  204. Gilead Sciences Launches Stop Hep B Campaign - (02/10/06)
     
  205. Idenix/Novartis Apply for Telbivudine European OK - (02/08/06)
     
  206. Treatment with Peg-Interferon a-2b for HBeAg-Positive Chronic Hepatitis B: HBsAg Loss Is Associated with HBV Genotype - (02/08/06)
     
  207. Therapeutic Options for Chronic Hepatitis B: Considerations and Controversies, part 1 - (02/02/06)
     
  208. Looking to the Future: New Agents for Chronic Hepatitis B, part 2 - (02/02/06)
     
  209. Advancing Patient Care: Integrating New Data, part 3 - (02/02/06)
     
  210. Selecting Appropriate Management Strategies for Chronic Hepatitis B: Who to Treat, part 4 - (02/02/06)
     
  211. Optimizing Management Strategies in Special Patient Populations, part 5 - (02/02/06)
     
  212. Introduction to Chronic Hepatitis B Infection, last part 6 of 6 - (02/02/06)
     
  213. Major role of hepatitis B genotypes in liver fibrosis during coinfection with HIV: HBV genotype G found to be associated with liver fibrosis - (01/31/06)
     
  214. Confronting chronic hepatitis B virus infection in HIV: new diagnostic tools and more weapons - (01/31/06)
     
  215. HBV+HCV+HDV-dynamic diseases when in combination - (01/30/06)
     
  216. Vaccination of Infants of Hepatitis B Mothers - (01/30/06)
     
  217. Virologic response and resistance to adefovir in patients with chronic hepatitis B, & Entecavir Salvage Therapy - (01/25/06)
     
  218. Candidates for therapy: HBV - (01/24/06)
     
  219. Hepatotoxicity of antiretrovirals: Incidence, mechanisms and management - (01/24/06)
     
  220. Natural history of chronic hepatitis B in co-infected patients - (01/24/06)
     
  221. "Chemoprevention of hepatocellular carcinoma in chronic hepatitis B with lamivudine?" - (01/23/06)
     
  222. Viral covalently closed circular DNA in a non-transgenic mouse model for chronic hepatitis B virus replication - (01/23/06)
     
  223. Management of hepatocellular carcinoma in HIV- infected patients - (01/23/06)
     
  224. Intl Coinfection Wrkshp: HBV Drug Resistance & Cross-Resistance (01/20/06)
     
  225. Intl Coinfection Wrkshp: New Drugs for HCV & HBV (01/17/06)
     
  226. New Drug HepeX-B To Prevent HBV Post-Transplant Reinfection - (01/04/06)
     
  227. Telbivudine Continues to Show Superior Efficacy over Lamivudine in Chronic HBV in Continuing GLOBE trial, 18 Mos: Presented at HEP DART - (01/04/06)
     
  228. Adefovir Dipivoxil Produces sustained improvement in HBV over Long-Term; Presented at HEP DART - (01/04/06)
     
  229. New HBV Drug Telbivudine: NDA submitted to FDA - (01/04/06)
     
  230. HBV DNA (viral load) Predicts Risk for Liver Cancer - (01/04/06)
     
  231. EACS: HAART & SVR in APRICOT Study (12/29/05)
     
  232. Dynavax's HEPLISAV(TM) Hepatitis B Vaccine Shows Statistically Significant Efficacy In Phase 2/3 Clinical Trial - (12/21/05)
     
  233. Impact of tenofovir-containing ART on chronic HBV in a cohort co-infected with HIV - (12/12/05)
     
  234. Treat HBV Immediately Upon Detecting Genotypic Resistance - (12/08/05)
     
  235. AASLD: Pradefovir, New HBV Drug: 24 Wks (12/05/05)
     
  236. AASLD: 5 Years Adefovir in HBeAg-Negatives (12/05/05)
     
  237. AASLD: Clevudine, new HBV Drug: 24 week study results (12/05/05)
     
  238. AASLD: Long-term effect of tenofovir in the treatment of lamivudine-resistant HBV in comparison to adefovir (12/02/05)
     
  239. AASLD: Normal ALT & Low HBV-DNA May Be Risk for Cirrhosis & HCC (11/28/05)
     
  240. AASLD: Serum Leptin Level Associated with Severity of Liver Fibrosis & Decreased After Pegasys Treatment in Chronic Hepatitis B (11/28/05)
     
  241. AASLD: Low Rate of Viral Rebound Seen in HBV Patients Treated With Entecavir (11/28/05)
     
  242. AASLD: Entecavir 2 Years Study Results in HBeAg+ HBV+ Patients (study ETV-22) (11/16/05)
     
  243. AASLD: Five-Year Data Evaluating Long-Term Therapy with Hepsera for Hepatitis B ''e'' Antigen-Negative Chronic Hepatitis B Presented at AASLD Annual Meeting (11/15/05)
     
  244. AASLD: BARACLUDE (entecavir) TWO-YEAR DATA ANALYSIS DID NOT DETECT EMERGENCE OF RESISTANCE IN NUCLEOSIDE-NAIVE CHRONIC HEPATITIS B PATIENTS (11/14/05)
     
  245. AASLD: SEVERE IMPAIRMENT IN QUALITY OF LIFE IN HIV+ WITH HCV BUT NOT WITH HBV (11/14/05)
     
  246. AASLD: HEPATITIS B: SCIENCE & TREATMENT 2005 (11/11/05)
     
  247. New Liver Cancer Therapy Approach Improves Survival - (11/07/05)
     
  248. Effects of chronic liver disease on bone mineral density and bone metabolism markers in postmenopausal women - (11/07/05)
     
  249. INTERFERON THERAPY FOR CHRONIC HEPATITIS B and Combination Interferon + Lamivudine - (11/07/05)
     
  250. HCC (Liver Cancer) Deaths Doubled & Hospital Services Costs Increase Significantly - (11/05/05)
     
  251. Entecavir RESISTANCE - (11/03/05)
     
  252. Hepatitis B Survey Among Asians Highlights Lack of Information About HBV - (11/03/05)
     
  253. Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: Antiviral and immunological activity - (11/03/05)
     
  254. Entecavir Treatment for HBV in Woodchucks - (10/27/05)
     
  255. Natural history of chronic HBV infection: A cohort study with up to 12 years follow-up in North Greece (part of the Interreg I-II/EC-project) - (10/27/05)
     
  256. Epidemiology, Natural History, Impact of Therapy of Hepatitis B - (10/24/05)
     
  257. Hepatits B Treatment - (10/24/05)
     
  258. "Predicting survival in hepatitis B" Should Targeted HBV DNA Suppression Be the Goal of Therapy? - (10/21/05)
     
  259. Hep B Booster Shot Unnecessary: Study - (10/21/05)
     
  260. Hepatitis B and Liver Transplantation - (10/21/05)
     
  261. The impact of maternal HBsAg carrier status on pregnancy outcomes: A case-control study - (10/14/05)
     
  262. Hepatitis B in India: 3% HBsAg+ - (10/13/05)
     
  263. Long-Term Interferon+Lamivudine for HBV in HBeAg-Negatives - (10/13/05)
     
  264. Hepatitis B Vaccine: is it associated with Autism? - (10/11/05)
     
  265. Resistance to adefovir: A new challenge in the treatment of chronic hepatitis B - (10/11/05)
     
  266. Adefovir Resistance: clinical outcomes - (10/11/05)
     
  267. Asian Americans & Hepatitis B - (10/06/05)
     
  268. New HCV Drug NM283 HBV Drug LdT at AASLD - (10/03/05)
     
  269. New HBV Therapy Research for siRNAs - (10/03/05)
     
  270. Hepatitis B in children: Complexities in management - (10/03/05)
     
  271. NIH Hepatitis B Management Conference: 2006 - (09/28/05)
     
  272. Broadeining Hepatitis B Vaccination considered for all adults - (09/21/05)
     
  273. Hepatitis B and HIV co-infection in sub-Saharan Africa: a call for further investigation - (09/21/05)
     
  274. 6.3% Prevalence of hepatitis B and C in pregnant women who are infected with HIV - (09/21/05)
     
  275. Adefovir-lamivudine combination therapy and hepatitis B viral kinetics - (09/20/05)
     
  276. Covalently Closed Circular DNA Is the Predominant Form of Duck Hepatitis B Virus DNA That Persists following Transient Infection.....inactive/nonreplicating cccDNA - (09/20/05)
     
  277. Peginterferon for HBV Therapy: review of studies - (09/19/05)
     
  278. September is Liver Cancer Awareness Month - (09/19/05)
     
  279. (Marijuana/Hash) Endocannabinoids and liver disease - review - (09/19/05)
     
  280. Stressgen Granted U.S. Patent Covering Therapeutic Products to Treat Hepatitis B Virus - (09/06/05)
     
  281. HBV, pathogenesis and natural course - (09/06/05)
     
  282. Promising Therapy for Human Hepatoma (liver cancer, HCC): Telomerase Inhibition by GRN163 - (09/13/05)
     
  283. Single (B or C), dual (BC or BD) and triple (BCD) viral hepatitis in HIV-infected patients in Madrid, Spain - (09/13/05)
     
  284. Pegasys for HBV: what is the treatment role? - (09/06/05)
     
  285. HBV Genotype May Predict Cirrhosis - (09/06/05)
     
  286. Does HBV Genotype Predict Response to IFN - (09/06/05)
     
  287. Relationship of genotypes of hepatitis B virus to mutations, disease progression and response to antiviral therapy - (08/15/05)
     
  288. Telbivudine (LdT) Achieves Primary Endpoint in Phase III GLOBE Trial, Largest Ever Registration Trial in HBV - (08/04/05)
     
  289. Gilead Announces Initiation of Phase III Study of Tenofovir for the Treatment of Chronic Hepatitis B Virus - (07/22/05)
     
  290. New Hep B Drug Pradefovir: 24 week data - (07/22/05)
     
  291. Peginterferon more effective than lamivudine for chronic hepatitis B - (07/05/05)
     
  292. Long-Term Therapy Required for HBeAg-Negative Patients: Adefovir HBV Therapy in HBeAg-negative Patients Maintains Benefits on Therapy for 144 Weeks; Upon Discontinuation of Therapy Rebound Occurs - (06/30/05)
     
  293. The Maze of Treatments for Hepatitis B - (06/30/05)
     
  294. Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B - (06/30/05)
     
  295. Long-Term Therapy with Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B - (06/30/05)
     
  296. Pharmasset to Develop Clevudine for the Treatment of Chronic Hepatitis B under a License from Bukwang Pharmaceuticals - (06/28/05)
     
  297. Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: A two-year study - (06/27/05)
     
  298. DDW: Resistance to Adefovir (Hepsera) Can Be Associated with Significant Virologic Breakthough and Fatal Hepatic Decompensation (06/20/05)
     
  299. HBV & Risk for Cancers Outside the Liver - (06/01/05)
     
  300. New HCV & HBV Drugs: toll-like receptors - (06/01/05)
     
  301. New Perspectives in the Treatment of HBeAg-positive and HBeAg-negative Chronic Hepatitis B pegylated interferon - (05/31/05)
     
  302. Hepatitis virus-positive livers OK for transplants - (05/27/05)
     
  303. HBV Drug LdT: 2 years followup: Phase IIb Extended-Treatment Trial of Telbivudine (LdT) vs. Lamivudine vs. Combination Treatment in Hepatitis B Patients: Two-Year Results - (05/26/05)
     
  304. New Perspectives in the Treatment of HBeAg-positive and HBeAg-negative Chronic Hepatitis B - (05/25/05)
     
  305. Hepatitis virus-positive livers OK for transplants - (05/27/05)
     
  306. HBV Drug LdT: 2 years followup: Phase IIb Extended-Treatment Trial of Telbivudine (LdT) vs. Lamivudine vs. Combination Treatment in Hepatitis B Patients: Two-Year Results - (05/26/05)
     
  307. Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate - (05/25/05)
     
  308. DDW: HBV DNA Elevations & Risk for Liver Cancer (05/23/05)
     
  309. DDW: HBV Viral Load Predicts Cirrhosis Risk (05/19/05)
     
  310. DDW: "Viral Load is a Strong Predictor of Hepatocellular Carcinoma (HCC) Risk in People Chronically Infected With Hepatitis B Virus (HBV) Independent of Serum Alanine Aminotransaminase Level (ALT)" (05/19/05)
     
  311. DDW: Entecavir 24 Week Followup Off-Treatment in HBeAg+ (05/19/05)
     
  312. DDW: HEPATITIS B: SCIENCE & TREATMENT 2005 (05/16/05)
     
  313. DDW: Pioglitazone Improves Fatty Liver (05/16/05)
     
  314. FDA Approves Pegasys(R) as the First and Only Pegylated Interferon for the Treatment of Chronic Hepatitis B   - (05/16/05)
     
  315. Can HBV Replicate Extrahepatically? - (05/16/05)
     
  316. HIV-infected patients with isolated anti-HBc antigen may require HBV vaccine - (05/13/05)
     
  317. Tenofovir Dosing in HBV - (05/09/05)
     
  318. Effect of Lamivudine Therapy on the Serum Covalently Closed-Circular (ccc) DNA of Chronic Hepatitis B Infection - (05/09/05)
     
  319. Is HBV Curable: effect of lamivudine (3TC) on cccDNA - (05/09/05)
     
  320. Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B - (05/09/05)
     
  321. Hepatitis B Immunity in United States Military Recruits - (05/09/05)
     
  322. May 13 is Hepatitis B Awareness Day - (05/09/05)
     
  323. EASL: Lack of Pharmacokinetic Interaction When Entecavir is Co-Administerd with Lamivudine,, Adefovir, or Tenofovir and Entecavir Dosing with Renal Impairment (05/05/05)
     
  324. EASL: HBV DNA (viral load) Predicts Liver Cirrhosis (05/02/05)
     
  325. EASL: Tenofovir in HIV/HBV Coinfection (05/02/05)
     
  326. EASL: Effect of Previous HBV Therapy on Pegasys+Lamivudine for HBV (05/02/05)
     
  327. EASL: HBV Viral Load Risk Factor for Liver Cancer (04/27/05)
     
  328. EASL: Diabetes & Lipids Associated with Liver Disease (04/27/05)
     
  329. EASL: Adefovir for HBV HBeAg-negative: 4 years- safety, antiviral efficacy, resistance, ALT normalization, creatinine & phosphorous (04/27/05)
     
  330. EASL: HBV DNA Decline & ALT Normalization Associated with Histologic Improvement (04/27/05)
     
  331. EASL: Pegasys for HBV, 72 Weeks: HBsAg Seroconversion Response (04/26/05)
     
  332. EASL: SUSTAINED RESPONSE TO PEGASYS IN HBeAg-NEGATIVE CHRONIC HEPATITIS B. (04/25/04)
     
  333. EASL: Adefovir Resistance report: 4 years update (04/22/05)
     
  334. EASL: Adefovir Week 144 Efficacy in HBeAg+ (04/20/05)
     
  335. EASL: HBV: Entecavir Compared to Adefovir & Lamivudine (04/20/05)
     
  336. EASL: Valtorcitabine (LdC) New HBV Drug Phase I/II Study Results (04/19/05)
     
  337. EASL: PegIFN+Adefovir Combination for HBV: cccDNA, seroconversion (04/19/05)
     
  338. EASL:Adefovir HBV Resistance Update (04/15/05)
     
  339. Effect of Antiviral Treatment with Entecavir on Age- and Dose-Related Outcomes of Duck Hepatitis B Virus Infection - (04/14/05)
     
  340. Dual hepatitis B virus and hepatitis C virus infection: To treat or not to treat, and how? EDITORIAL - (04/09/05)
     
  341. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort (04/06/05)
     
  342. HBV DNA Can Persist After HBsAg Seroconversion (04/05/05)
     
  343. Hepatitis B or hepatitis C and HIV (04/05/05)
     
  344. Occult Hepatitis B May Progress to Cirrhosis & Liver Cancer Editorial (04/05/05)
     
  345. 1st Study of Occult Hepatitis B prevalence in Community Setting (04/05/05)
     
  346. FDA Approves New Treatment Baraclude (entecavir) for Chronic Hepatitis B (03/31/05)
     
  347. FDA Antiviral Drug Advisory Committee Recommends Unanymously to Approve Entecavir for Hepatitis B (03/15/05)
     
  348. ART May Reconstitute HBV Immunity (03/15/05)
     
  349. Disease Status & Therapeutic End Points in Hepatitis B (03/09/05)
     
  350. CROI: "Entecavir in HIV/HBV Co-Infected Patients: Safety and Efficacy in a Phase II Study (ETV-038)" - (03/08/05)
     
  351. CROI: Tenofovir for HBV/HIV Coinfection - (03/03/05)
     
  352. PegIntron+Lamivudine vs LAM for HBV - (03/01/05)
     
  353. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel - (02/24/05)
     
  354. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA - (02/16/05)
     
  355. Hepatitis B or Hepatitis C and HIV-infection Diagnosis/Care/Treatent - (02/11/05)
     
  356. Study Finds Interferon Reduces Cancer Risk in HCV+ Cirrhotics - (02/10/05)
     
  357. Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance - (02/10/05)
     
  358. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma (liver cancer) - (02/09/05)
     
  359. The value and limitations of long-term nucleoside antiviral therapy in chronic hepatitis B - (02/09/05)
     
  360. Liver & Kidney Transplant in HIV Study - (02/03/05)
     
  361. Chronic Hepatitis B & HIV/HBV Coinfection - (01/31/05)
     
  362. Hepatitis New Drug Research - (01/26/05)
     
  363. Pegasys Receives Positive Opinion for HBV in Europe; HBV/HIV Coinfection Medical Management - (01/24/05)
     
  364. The potential of RNA interference as a tool in the management of viral hepatitis - (01/13/05)
     
  365. PegIntron with or without 3TC for Hepatitis B Treatment - (01/07/05)
     
  366. Hepatitis B in the Human Immunodeficiency Virus-Infected Patient: Epidemiology, Natural History, and Treatment - (12/30/05)
     
  367. Medicinal Herbs for HCV (oxymatrin) - (12/30/05)
     
  368. PEGASYS Approved for Chronic Hepatitis B in Switzerland - (12/28/05)
     
  369. Management of hepatitis B patients with antiviral resistance - (12/21/05)
     
  370. Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment - (12/15/05)
     
  371. Waning immunity to plasma-derived hepatitis B vaccine and the need for boosters 15 years after neonatal vaccination - (12/13/05)
     
  372. AASLD: Entecavir Resistance - (11/16/05)
     
  373. AASLD: LB80380, new HBV Drug - (11/15/05)
     
  374. AASLD: PegIFN for HBV, HDV, & HCV - (11/10/05)
     
  375. AASLD: ADEFOVIR FOR HBV- 144 WEEK FOLLOW-UP - (11/10/05)
     
  376. AASLD: CLINICAL PHARMACOKINETICS OF TELBIVUDINE, A POTENT ANTIVIRAL FOR HEPATITIS B, IN SUBJECTS WITH IMPAIRED HEPATIC OR RENAL FUNCTION - (11/09/05)
     
  377. AASLD: LdT & HBV Therapy Viral Dynamics - (11/09/05)
     
  378. AASLD: LdC, new HBV Drug: 4-week Dosing, Safety & Antiviral Efficacy Study - (11/08/05)
     
  379. AASLD: Remofovir, new HBV drug: prodrug of PMEA - (11/08/05)
     
  380. AASLD: Clevudine, new HBV drug, 3 studies - (11/08/05)
     
  381. AASLD: FTC for HBV - (11/08/05)
     
  382. AASLD: LdT, new HBV Drug: week 52 phase II results; Viral Dynamics - (11/08/05)
     
  383. AASLD: In Vitro Cross-Resistance HBV Drugs - (11/08/05)
     
  384. AASLD: Pegasys+Lamivudine, Pegasys, or Lamivudine for HBV Therapy - (11/05/05)
     
  385. AASLD: Entecavir in Lamivduine Experienced Patients - (11/05/05)
     
  386. AASLD: Entecavir: new HBV drug, phase III study in nucleoside-naïve HBeAg-negative patients - (11/02/05)
     
  387. AASLD: Entecavir: new hepatitis B drug-phase III study results of 48-weeks therapy in HBeAg+ nucleoside-naïve patients - (11/01/05)
     
  388. AASLD: Report 1 on Hepatitis B at the Liver Conference AASLD - (11/01/05)
     
  389. Review article: current management of chronic hepatitis B - (10/25/05)
     
  390. Occult hepatitis B in HCV+ - (10/25/05)
     
  391. High Prevalence of HBV in HIV+ & HIV- Women -WIHS - (10/21/05)
     
  392. Treatments for Hepatitis B - (10/19/05)
     
  393. Occult HBV Seen in 26% of HCV+ - (10/14/05)
     
  394. Prevention of (HBV) Hepatocellular Carcinoma - (10/08/05)
     
  395. Lamivudine Reduced Risk of Hepatic Decompensation & Liver Cancer by Half - (10/08/05)
     
  396. Valeant Pharmaceuticals to Present New HBV Drug Remofovir Pharmacokinetic and Pharmacodynamic Data From Phase 1 Clinical Trial - (10/07/05)
     
  397. Significance of HBV DNA Levels in Liver Histology of HBeAg and Anti-HBe Positive Patients with Chronic Hepatitis B - (10/07/05)
     
  398. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study - (10/05/05)
     
  399. Entecavir, New Hep B Drug, BMS Files NDA with FDA - (10/05/05)
     
  400. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine - (09/30/05)
     
  401. Hepatitis B virus genotypes: Do they play a role in the outcome of HBV infection? - (09/30/05)
     
  402. Genotype C HBV-infection is associated with an increased risk of hepatocellular carcinoma - (09/29/05)
     
  403. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures - (09/28/05)
     
  404. Hepatitis B virus genotype C linked to increased hepatocellular carcinoma risk - (09/24/05)
     
  405. High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing lamivudine resistance - (09/22/05)
     
  406. Combination Therapy in HBV: will it improve response? - (09/22/05)
     
  407. Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B - (09/22/05)
     
  408. HBV/HIV Coinfection Medical Management - (09/20/05)
     
  409. Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B - (09/16/05)
     
  410. Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients - (09/03/05)
     
  411. A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection - (09/03/05)
     
  412. Risk of HIV & Hepatitis Infections From Blood & Tissue Donors - (08/25/05)
     
  413. Outcome of liver transplantation for hepatitis B in the United States - (08/09/05)
     
  414. HEPATITIS B IN CORRECTIONAL FACILITIES: hi prevalence & successful vaccination programs - (08/09/05)
     
  415. Quantitation of hepatitis B lamivudine resistant mutants by real-time amplification refractory mutation system PCR - (08/09/05)
     
  416. A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B - (08/05/05)
     
  417. Roche Files for Application with FDA to Market Pegasys for Chronic Hepatitis B Treatment - (07/22/05)
     
  418. XV International AIDS Conference in Bangkok: Adefovir for HBV/HIV Coinfection with 3TC Resistance: 4 years followup - (07/19/05)
     
  419. FDA UPDATE ON VIREAD (TENOFOVIR) LABEL - (07/06/05)
     
  420. Hepatitis B Transmission in Prisons: sharing needles, sex, mother-to-child, vaccine for prevention - (07/06/05)
     
  421. Isolated Presence of Antibody to Hepatitis B Core Antigen in Patients Coinfected With HIV - (06/30/05)
     
  422. Efficacy of Tenofovir Disoproxil Fumarate in Antiretroviral Therapy--Naive and --Experienced Patients Coinfected with HIV-1 and Hepatitis B Virus - (06/28/05)
     
  423. Long-term benefit of interferon therapy of chronic hepatitis D: regression of advanced hepatic fibrosis - (06/22/05)
     
  424. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy - (06/22/05)
     
  425. Occult Hepatitis B in HIV-Infected Patients - (06/22/05)
     
  426. DDW: Significant and Sustained Efficacy of Adefovir After 4 Years of Treatment in Chronic HBV Patients with Lamivudine-Resistant HBV and HIV Coinfection - (05/25/05)
     
  427. DDW: Three year Results from a Double-Blind, Randomized, Pacebo-Controlled, Study of Adefovir (ADV) in HBeAg-negative Chronic Hepatitis B (CHB) - (05/25/05)
     
  428. DDW: Combination of Pegylated IFN and Lamivudine is superior to Lamivudine alone in the treatment of HBV - (05/24/05)
     
  429. DDW: ADEFOVIR RESISTANCE REPORT - (05/20/05)
     
  430. DDW: Adefovir Reduced HBV Viral Reservoir & HBsAg in Parallel - (05/20/05)
     
  431. Occult HBV: Clinical Significance of Hepatitis B Core Antibody Positivity in HCV-Infected and HCV/HIV Coinfected Individuals - (05/10/05)
     
  432. HBV/HIV Coinfection & Tenofovir - (05/10/05)
     
  433. EASL: The Long-Term Outcome of HBeAg-negative Patients with Cirrhosis Treated with Lamivudine Monotherapy: a 5 year prospective cohort - (04/27/05)
     
  434. EASL: Long-Term Incidence of Adefovir Resistance in Chronic Hepatitis B Patients after 144 weeks of Therapy - (04/27/05)
     
  435. EASL: DURABILITY OF HBeAg SEROCONVERSION AFTER ADEFOVIR DIPIVOXIL TREATMENT FOR CHRONIC HEPATITIS B - (04/27/05)
     
  436. EASL: Adefovir 3 Year Study Results in Presumed Precore Mutant Chronic Hepatitis B: safety and efficacy - (04/27/05)
     
  437. EASL: HBsAg Seroconversion in Adefovir Treated Chronic Hepatitis B Patients - (04/26/05)
     
  438. EASL: Entecavir Resistance in Lamivudine Resistant Patients - (04/26/05)
     
  439. EASL: Results of a 1-Year International Phase IIB Trial of LdT, and LdT plus Lamivudine, in Patients with Chronic Hepatitis B - (04/26/05)
     
  440. EASL: EASL Hepatitis B Report 2: Pegasys Study in Hepatitis B - (04/22/05)
     
  441. Hepatitis A - (04/05/05)
     
  442. HBV Epidemiology - (04/02/05)
     
  443. Interferon for HBV Can Increase Survival & Risk for Developing Liver Cancer: study authors recommend interferon as first-line therapy - (04/02/05)
     
  444. CROI: Quantification of Hepatitis B Virus-specific T-cell Responses in HIV/HBV Co-infected Individuals - (03/15/05)
     
  445. Hepatitis B: Treatment Strategies for Currently Available Drugs - (03/08/05)
     
  446. CROI: Tenofovir is Effective Against HBV in HBV/HIV Coinfection - (03/03/05)
     
  447. CROI: Hepatitis B Treatment Update - Nancy Shulman, MD, Stanford University (03/02/05)
     
  448. CROI: Three Year Treatment with Adefovir in Chronic Hepatitis B Patients with Lamivudine (3TC) Resistant HBV and HIV Coinfection Results in Significant and Sustained Clinical Improvement - (03/02/05)
     
  449. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States - (02/05/05)
     
  450. HEP DART: Differences between Hepatitis B and C in the Prediction of Success of Treatment Using Early Viral Kinetics - (01/26/05)
     
  451. HEP DART: Clinical Development of Entecavir for the Treatment of Chronic Hepatitis B - (01/26/05)
     
  452. HEP DART: L-Thymidine (LdT) and Related Compounds - (01/26/05)
     
  453. HEP DART: A 12 Week Randomized Placebo-Controlled Double Blind Trial of Clevudine in Patients with Chronic Hepatitis B with Post-Treatment Follow-up for 24 weeks - (01/26/05)
     
  454. HHV-8 seropositivity linked with prostate cancer - (01/26/05)
     
  455. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B - (01/15/05)
     
  456. EDITORIAL: Occult hepatitis B virus infection in patients with hepatocellular carcinoma: Innocent bystander, cofactor, or culprit? - (01/15/05)
     
  457. EDITORIAL: Rescue therapy for drug resistant hepatitis B: Another argument for combination chemotherapy? - (01/15/05)
     
  458. Viral features of lamivudine resistant hepatitis B genotypes A and D - (01/14/05)
     
  459. High prevalence of occult hepatitis B in Baltimore injection drug users - (01/14/05)
     
  460. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection - (01/14/05)
     
  461. Viral features of lamivudine resistant hepatitis B genotypes A and D - (01/14/05)
     
  462. Oral feeding of hepatitis B proteins a promising treatment for chronic infection - (01/05/05)
     
  463. Hepatitis B Rates in the United States - (01/05/05)
     
  464. Incidence of Acute Hepatitis B - United States, 1990-2002 - (01/05/05)